Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
Abstract The advent of immunotherapy represents a significant breakthrough in cancer treatment, with immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 demonstrating remarkable therapeutic efficacy. However, patient responses to immunotherapy vary significantly, with immunosuppression wit...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-024-02208-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544922229899264 |
|---|---|
| author | Shuyan He Lu Zheng Chunjian Qi |
| author_facet | Shuyan He Lu Zheng Chunjian Qi |
| author_sort | Shuyan He |
| collection | DOAJ |
| description | Abstract The advent of immunotherapy represents a significant breakthrough in cancer treatment, with immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 demonstrating remarkable therapeutic efficacy. However, patient responses to immunotherapy vary significantly, with immunosuppression within the tumor microenvironment (TME) being a critical factor influencing this variability. Immunosuppression plays a pivotal role in regulating cancer progression, metastasis, and reducing the success rates of immunotherapy. Myeloid-derived suppressor cells (MDSCs), due to their potent immunosuppressive capabilities, emerged as major negative regulators within the TME, facilitating tumor immune evasion by modulating various immune cells. In addition to their immunosuppressive functions, MDSCs also promote tumor growth and metastasis through non-immunological mechanisms, such as angiogenesis and the formation of pre-metastatic niches. Consequently, MDSCs in the TME are key regulators of cancer immune responses and potential therapeutic targets in cancer treatment. This review describes the origins and phenotypes of MDSCs, their biological roles in tumor progression, and regulatory mechanisms, with a focus on current therapeutic approaches targeting tumor-associated MDSCs. Furthermore, the synergistic effects of targeting MDSCs in combination with immunotherapy are explored, aiming to provide new insights and directions for cancer therapy. |
| format | Article |
| id | doaj-art-32477942459542369b0f88325c8d1712 |
| institution | Kabale University |
| issn | 1476-4598 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj-art-32477942459542369b0f88325c8d17122025-01-12T12:10:27ZengBMCMolecular Cancer1476-45982025-01-0124112410.1186/s12943-024-02208-3Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapyShuyan He0Lu Zheng1Chunjian Qi2Department of Tumor Center, The Affiliated Jiangyin Hospital of Nantong UniversityClinical Medical Research Center, The Third Affiliated Hospital of Soochow UniversityLaboratory of Oncology, Basic Research Center, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical UniversityAbstract The advent of immunotherapy represents a significant breakthrough in cancer treatment, with immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 demonstrating remarkable therapeutic efficacy. However, patient responses to immunotherapy vary significantly, with immunosuppression within the tumor microenvironment (TME) being a critical factor influencing this variability. Immunosuppression plays a pivotal role in regulating cancer progression, metastasis, and reducing the success rates of immunotherapy. Myeloid-derived suppressor cells (MDSCs), due to their potent immunosuppressive capabilities, emerged as major negative regulators within the TME, facilitating tumor immune evasion by modulating various immune cells. In addition to their immunosuppressive functions, MDSCs also promote tumor growth and metastasis through non-immunological mechanisms, such as angiogenesis and the formation of pre-metastatic niches. Consequently, MDSCs in the TME are key regulators of cancer immune responses and potential therapeutic targets in cancer treatment. This review describes the origins and phenotypes of MDSCs, their biological roles in tumor progression, and regulatory mechanisms, with a focus on current therapeutic approaches targeting tumor-associated MDSCs. Furthermore, the synergistic effects of targeting MDSCs in combination with immunotherapy are explored, aiming to provide new insights and directions for cancer therapy.https://doi.org/10.1186/s12943-024-02208-3TMEMDSCsImmunotherapyImmunosuppressionTherapeutic targets |
| spellingShingle | Shuyan He Lu Zheng Chunjian Qi Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy Molecular Cancer TME MDSCs Immunotherapy Immunosuppression Therapeutic targets |
| title | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy |
| title_full | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy |
| title_fullStr | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy |
| title_full_unstemmed | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy |
| title_short | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy |
| title_sort | myeloid derived suppressor cells mdscs in the tumor microenvironment and their targeting in cancer therapy |
| topic | TME MDSCs Immunotherapy Immunosuppression Therapeutic targets |
| url | https://doi.org/10.1186/s12943-024-02208-3 |
| work_keys_str_mv | AT shuyanhe myeloidderivedsuppressorcellsmdscsinthetumormicroenvironmentandtheirtargetingincancertherapy AT luzheng myeloidderivedsuppressorcellsmdscsinthetumormicroenvironmentandtheirtargetingincancertherapy AT chunjianqi myeloidderivedsuppressorcellsmdscsinthetumormicroenvironmentandtheirtargetingincancertherapy |